The Role of Anti-VEGF/Angiopoiten-2 Inhibition for the Treatment of AMD and DME

home / state-of-sciences-presentations / the-role-of-anti-vegf-angiopoiten-2-inhibition-for-the-treatment-of-amd-and-dme

Experts discuss the challenges of treatment burden in retinal disease management, emphasizing the importance of personalized treatment strategies to optimize patient outcomes. They also explore the role of shared decision-making and strategies for improving health literacy and numeracy in patient communication.

Overview of nAMD and DME

EP. 1: Overview of nAMD and DME

September 22nd 2023

Diana Do, MD, provides an overview of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).

Clinical Trial Overview: Wet AMD

EP. 2: Clinical Trial Overview: Wet AMD

Mark Barakat, MD

September 22nd 2023

Mark Barakat, MD, discusses the phase 3 TENAYA and LUCERNE trials for patients with neovascular age-related macular degeneration (nAMD).

Clinical Trial Overview: DME

EP. 3: Clinical Trial Overview: DME

Matthew Cunningham, MD, FASRS

September 22nd 2023

Matthew Cunningham, MD, FASRS, provides the highlights of the YOSEMITE and RHINE trials for patients with diabetic macular edema (DME).

Patient Communication and Shared Decision Making

EP. 4: Patient Communication and Shared Decision Making

Mark Barakat, MD

September 22nd 2023

Mark Barakat, MD, reviews the best practices for patient communication and shared decision making.

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.